Details

Autor(en) / Beteiligte

• Kitchen, S.
• Kershaw, G.
• Tiefenbacher, S.

Titel

Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues

Ist Teil von

• Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (S5), p.72-77

Ort / Verlag

England: Blackwell Publishing Ltd

Erscheinungsjahr

2016

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• The recent development of modified recombinant factor VIII (FVIII) and factor IX (FIX) therapeutic products with extended half‐lives will create challenges for the haemostasis laboratory in obtaining recovery estimates of these products in clinical samples using existing assays. The new long‐acting therapeutic concentrates contain molecular modifications of Fc fusion, site‐specific of polyethylene glycol or albumin fusion. The optimum methods for monitoring each new product will need to be assessed individually and laboratories should select an assay which gives similar results to the assay used to assign potency to the product in question. For some extended half‐life FVIII and FIX products some one stage assays are entirely unsuitable for monitoring purposes. For most products and assay reagents studied so far, and reviewed in this manuscript, chromogenic FVIII or FIX assays can be safely used with conventional plasma standards. If one stage assays are used then they should be performed using carefully selected reagents/methods which have been shown to recover activity close to the labelled potency for the specific product being monitored.